Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5093 in MET-Altered Advanced NSCLC
NCT04077099Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of davutamig in non-small cell lung cancer (NSCLC), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment-Emergent Adverse Events at 12 years and 5 more. Started Jan 2020; status: active, not recruiting.
02
Drugs
davutamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04077099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04077099.